US biotech company Novavax, a specialist in protein-based vaccines, has detailed its latest plans for job cuts to save funds for the cash-strapped company.
This comes after Novavax last year announced the goal of significantly reducing research and development (R&D) and selling, general and administrative (SG&A) expenses.
"The new Novavax is being designed to be a leaner and more agile organization"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze